What it is
BPC-157 is a synthetic chain of fifteen amino acids, sequence GEPPPGKPADDAGLV. It is almost always described as a fragment of a naturally occurring human protein, and that description does not survive checking.
The claim traces to one sentence in a 1993 paper from the group that named the compound, reporting a 40 kDa gastric protein isolated and a fifteen amino acid fragment characterised (Sikiric 1993). No publication reporting that protein isolation, purification or sequencing exists, and it has no UniProt or GenBank accession. The only primary description is a 1994 US patent, which an independent review found describes only crude chromatography and dialysis.
So the accurate description is narrower: a synthetic peptide claimed to correspond to a fragment of a protein nobody has characterised. Reviews published in 2025 and 2026 still call it naturally occurring.
The form sold as pentadeca arginate, or PDA, is the same sequence with arginine as the counter-ion instead of acetate. A salt, not a different peptide. No peer-reviewed study of it exists and the FDA review did not evaluate it.
How it works
No receptor has been identified, no binding affinity measured, and no knockout or knockdown experiment has demonstrated a required target. After roughly thirty-four years and about 230 papers, the molecular target is unknown. That constrains everything else on this page.
The vascular finding is the one that has held up
A group at Chang Gung University in Taiwan reported that BPC-157 raises VEGFR2 expression and activates a VEGFR2 to Akt to eNOS pathway, improving blood flow recovery in rat hindlimb ischaemia (Hsieh 2017), and separately reported nitric-oxide-mediated relaxation of isolated rat aorta (Hsieh 2020). In 2026 an unrelated Turkish group reproduced that relaxation in human arterial tissue, using internal mammary artery rings from twelve donors (Bilgic 2026).
Two unaffiliated groups, two species, one converging result. This is the only claim in the BPC-157 literature that meets an ordinary standard of independent replication.
Beyond that, the measured findings are mostly cell culture, and the broader framework claim, that BPC-157 works through a general interaction with the nitric oxide system, is asserted across dozens of papers from the originating group rather than demonstrated by any single experiment.
Research evidence
Human evidence: one clinic, thirty-one patients
Three published papers report giving BPC-157 to people and recording an outcome. All three share a first author and a journal.
- A retrospective chart review of intra-articular injection for knee pain. Seventeen patients, sixteen reached by telephone, only twelve of those on BPC-157 alone, rating pain from memory six months to a year later. The paper states that no specific tools were used to measure function, quality of life or stiffness. No control group (Lee 2021).
- A single-arm report in interstitial cystitis. Twelve women, no control group, 10 mg injected around the inflamed bladder area during cystoscopy, one procedure. Ten of twelve rated their symptoms fully resolved on a five-point subjective scale (Lee 2024).
- An intravenous safety pilot in two people, 10 mg then 20 mg. The paper notes that both participants had already received intravenous BPC-157 before enrolling (Lee 2025).
The cystitis result deserves a second look rather than a citation. Cystoscopy with bladder distension is itself associated with temporary relief in interstitial cystitis, so in a single-arm design with a subjective endpoint the procedure and the compound cannot be separated. The paper does not raise this.
Across all three, roughly thirty-one patients, none with a control group, every outcome self-reported, and all of it from one physician in Orlando, Florida.
The two controlled studies that are rarely mentioned
Two earlier human studies had a placebo arm, and both are absent from most popular accounts. Neither was published in full, so neither has a PubMed record, and both are visible only through the FDA briefing document.
- A randomised, placebo-controlled trial in mild to moderate ulcerative colitis. Fifty-three randomised, forty-six completed, 80 mg by rectal enema once daily for two weeks. Disease activity index change was minus 3.2 on BPC-157 against minus 1.6 on placebo, with confidence intervals that overlap. Conference abstract only.
- A tolerability study in twenty-four healthy volunteers, rectal enema up to 2 mg/kg daily for eight days. The reported result: BPC-157 was not detected in plasma samples. Conference abstract only.
That second finding is the only human measurement of whether BPC-157 reaches the circulation by any route, and it sits awkwardly beside a compound taken for systemic effect. FDA called the randomised data inadequate to support efficacy or safety.
Preclinical evidence
The animal and cell literature is large and reports benefit across an unusually wide range of models: gastric and duodenal ulcer, colitis, oesophagitis, intestinal anastomosis, short bowel syndrome, several fistula models, Achilles transection, tendon-to-bone detachment, transected quadriceps, ligament transection, traumatic brain injury, spinal cord compression, cerebral ischaemia, thrombosis and portal hypertension.
The breadth is itself a finding. A compound with no identified receptor improving outcomes in nearly every tissue and nearly every injury model is a pattern that calls for a mechanism, and none has been offered that would predict it.
The concentration problem
Of 230 papers indexed in PubMed on BPC-157, about 176, roughly 77 percent, carry Predrag Sikiric of the University of Zagreb as an author. Around 143 of those are primary research reports from that group. Sven Seiwerth, the group pathologist, appears on 163 of the 230. Counting carefully through the remainder, about fifteen papers, roughly 6.5 percent of the corpus, are primary biological studies by a group with no connection to Zagreb or to Pliva, the Croatian pharmaceutical company that licensed the compound.
Thirty-plus years, dozens of journals, one laboratory. That is not an accusation. It is why the independent work matters more than its volume suggests.
The first independent test of the tendon claim
Tendon healing is the claim BPC-157 is best known for, and until 2026 no unaffiliated group had tested it in a live animal. In July 2026 a Turkish group transected and repaired the Achilles tendon in thirty-two rats, giving BPC-157 at 10 micrograms per kilogram per day intraperitoneally, the exact dose and route of the original Zagreb work, for four weeks (Bicer 2026).
BPC-157 did not reach statistical significance on maximum load to failure, on the total Bonar score, or on the total Movin score, and showed no significant difference in collagen type I expression. The authors describe numerically lower scores that did not reach significance. TB-500, included as a comparator in the same experiment, did reach significance on all three.
One study is one study, and a single negative result settles nothing that the positive results have not settled either. It is here because it is the first independent in vivo attempt at the flagship claim, at the originators own dose.
The dose that does not behave like a dose
The standard design in the Zagreb animal work gives three doses in the same experiment: 10 micrograms, 10 nanograms and 10 picograms per kilogram, a range spanning one million fold. Comparable benefit is reported at all three, and the group calls this an equipotent dosage, framing it as a property of the compound.
A receptor-mediated agent with a flat response across six orders of magnitude has no standard pharmacological interpretation. No independent group has tested it and no mechanistic account of it has been published.
The practical consequence matters more than the puzzle. Every dose conversion in circulation is built on those animal figures, and if 10 picograms per kilogram works as well as 10 micrograms, there is no dose to convert.
Safety
There is no human safety data at any duration beyond two weeks, by any route. The longest documented human exposure anywhere in the record is the two-week enema study described above.
The FDA gap list from the July 2026 advisory committee is specific. No acute toxicity study by any nominated route, meaning oral, rectal, subcutaneous or nasal. No repeat-dose toxicity by any of those routes, the only such data being a 28-day intramuscular set. No carcinogenicity study identified at all, which for an agent that raises VEGFR2 and promotes vessel growth is the most consequential absence on the list.
The 28-day intramuscular studies did produce signals: shortening and prolongation of activated partial thromboplastin time in rats and dogs, which FDA described as suggestive of altered clotting properties, together with raised ALT, glucose and triglycerides.
Immunogenicity has not been assessed in any species, and FDA said the risk could not be ruled out given aggregation potential and missing impurity testing. Three FAERS reports involve injectable BPC-157, including diffuse hyperpigmentation with gingival darkening that recurred on re-use.
The originating group states in its reviews that no toxicity has been observed and that a lethal dose could not be reached. FDA reviewed the same material and did not accept it as adequate.
Regulatory status
BPC-157 is not an approved drug anywhere. No approved products, no pending applications, and no entry in the European, Japanese or International Pharmacopoeias.
It was nominated for the 503A bulk drug substances list in 2015 and 2018, placed in Category 2 in 2023 for immunogenicity and impurity concerns, and removed from that category in April 2026 because the nominations had been withdrawn. Removal does not make a substance eligible for compounding.
On 23 July 2026 the Pharmacy Compounding Advisory Committee voted to recommend adding it, against FDA staff, eight to six with one abstention, though one secondary analysis records eight to seven. FDA reviewers had found no evidence of effectiveness for the nominated indication, ulcerative colitis, and no study using the oral, subcutaneous, nasal or transdermal route in those patients. FDA has not acted, the vote is non-binding, and rulemaking would come first.
BPC-157 is not named individually on the WADA prohibited list but falls under class S0, non-approved substances, by the category definition. It is detectable in urine along with five metabolites.
Handling and identity
FDA found BPC-157 not well characterised physically or chemically, partly because the naming is inconsistent. Body Protection, Body Protective and Body Protecting Compound all appear in peer-reviewed papers for the same substance, as do the codes PL-10, PLD-116, PL 14736 and AK-15. BPC-15 is a different compound, and papers treating it as BPC-157 evidence are over-reading.
Per FDA, the lyophilised free base keeps about three weeks at room temperature, storage recommended below minus 18 degrees; in solution, two to three weeks at 4 degrees and three to four months at minus 20. It is sensitive to pH and heat, which drives aggregation.
Elimination half-life in rats and dogs is under thirty minutes, intramuscular bioavailability 14 to 19 percent in rats and 45 to 51 percent in dogs. No oral or subcutaneous figure exists in any species, which is worth holding next to the claim that the arginate form is 90 percent orally bioavailable. That figure appears in no peer-reviewed paper.